The group of plasma derivatives will seek to reduce the debt, of 6.9 times the EBITDA, through divestments, the freezing of the dividend and the brake on purchases.
Grifols has decided to entrust itself to financial discipline after studying a capital increase, which it has finally ruled out in the short term. Nuria Pascual, director of investor relations for the plasma derivatives multinational, read ay